Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders

Yuko Kuzuyama; Shoichiro Tsuda; Taku Seriu; Hiroyuki Nakai; Tsuyoshi Murakami; Teruyuki Takashima; Yukari Takahashi; Shinji Tanaka; Hitoshi Nakagawa; Hikari Nishigaki; Shouhei Yokota; Masafumi Taniwaki; Shinichi Misawa; Kei Kashima; Shigeo Horiike; Kazuhiro Nishida; Tsukasa Okuda

doi:10.11553/antibiotics1968b.45.523

Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders

Yuko Kuzuyama, Shoichiro Tsuda, Taku Seriu, Hiroyuki Nakai, Tsuyoshi Murakami, Teruyuki Takashima, Yukari Takahashi, Shinji Tanaka, Hitoshi Nakagawa, Hikari Nishigaki, Shouhei Yokota, Masafumi Taniwaki, Shinichi Misawa, Kei Kashima, Shigeo Horiike, Kazuhiro Nishida, Tsukasa Okuda

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Fifty patiens with infections associated with hematological disorders were treated with ceftazidime (CAZ). Among them 44 cases were evaluable, including 21 with acute leukemia, 17 with malignant lymphoma, and 6 with other hematological disorders. Excellent responses were obserbed in 15 patients (34.1%) and good responses in 15 (34.1%), with an overall efficacy rate of 68.2%. The efficacy rate among sepsis and suspected sepsis cases was 67.6%. This treatment was also effective in 7 of 10 cases in which neutrophil counts were less than 500/mm3 through the course of administration. Laboratory abnormalities included mild eosinophilia in 1 case, slight elevation of GOT in 1 case and slight elevation of GPT in 1 case. These results suggest that CAZ is an effective and safe antibiotics for the treatment of infections in patients with hematological disorders.

Original language	English (US)
Pages (from-to)	523-529
Number of pages	7
Journal	The Japanese Journal of Antibiotics
Volume	45
Issue number	5
DOIs	https://doi.org/10.11553/antibiotics1968b.45.523
State	Published - Feb 1992
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

Access to Document

10.11553/antibiotics1968b.45.523

Cite this

Kuzuyama, Y., Tsuda, S., Seriu, T., Nakai, H., Murakami, T., Takashima, T., Takahashi, Y., Tanaka, S., Nakagawa, H., Nishigaki, H., Yokota, S., Taniwaki, M., Misawa, S., Kashima, K., Horiike, S., Nishida, K., & Okuda, T. (1992). Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders. The Japanese Journal of Antibiotics, 45(5), 523-529. https://doi.org/10.11553/antibiotics1968b.45.523

Kuzuyama, Y, Tsuda, S, Seriu, T, Nakai, H, Murakami, T, Takashima, T, Takahashi, Y, Tanaka, S, Nakagawa, H, Nishigaki, H, Yokota, S, Taniwaki, M, Misawa, S, Kashima, K, Horiike, S, Nishida, K & Okuda, T 1992, 'Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders', The Japanese Journal of Antibiotics, vol. 45, no. 5, pp. 523-529. https://doi.org/10.11553/antibiotics1968b.45.523

@article{37ebe5644092434793fededdfdd7dd9a,

title = "Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders",

abstract = "Fifty patiens with infections associated with hematological disorders were treated with ceftazidime (CAZ). Among them 44 cases were evaluable, including 21 with acute leukemia, 17 with malignant lymphoma, and 6 with other hematological disorders. Excellent responses were obserbed in 15 patients (34.1%) and good responses in 15 (34.1%), with an overall efficacy rate of 68.2%. The efficacy rate among sepsis and suspected sepsis cases was 67.6%. This treatment was also effective in 7 of 10 cases in which neutrophil counts were less than 500/mm3 through the course of administration. Laboratory abnormalities included mild eosinophilia in 1 case, slight elevation of GOT in 1 case and slight elevation of GPT in 1 case. These results suggest that CAZ is an effective and safe antibiotics for the treatment of infections in patients with hematological disorders.",

author = "Yuko Kuzuyama and Shoichiro Tsuda and Taku Seriu and Hiroyuki Nakai and Tsuyoshi Murakami and Teruyuki Takashima and Yukari Takahashi and Shinji Tanaka and Hitoshi Nakagawa and Hikari Nishigaki and Shouhei Yokota and Masafumi Taniwaki and Shinichi Misawa and Kei Kashima and Shigeo Horiike and Kazuhiro Nishida and Tsukasa Okuda",

year = "1992",

month = feb,

doi = "10.11553/antibiotics1968b.45.523",

language = "English (US)",

volume = "45",

pages = "523--529",

journal = "The Japanese Journal of Antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "5",

}

TY - JOUR

T1 - Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders

AU - Kuzuyama, Yuko

AU - Tsuda, Shoichiro

AU - Seriu, Taku

AU - Nakai, Hiroyuki

AU - Murakami, Tsuyoshi

AU - Takashima, Teruyuki

AU - Takahashi, Yukari

AU - Tanaka, Shinji

AU - Nakagawa, Hitoshi

AU - Nishigaki, Hikari

AU - Yokota, Shouhei

AU - Taniwaki, Masafumi

AU - Misawa, Shinichi

AU - Kashima, Kei

AU - Horiike, Shigeo

AU - Nishida, Kazuhiro

AU - Okuda, Tsukasa

PY - 1992/2

Y1 - 1992/2

N2 - Fifty patiens with infections associated with hematological disorders were treated with ceftazidime (CAZ). Among them 44 cases were evaluable, including 21 with acute leukemia, 17 with malignant lymphoma, and 6 with other hematological disorders. Excellent responses were obserbed in 15 patients (34.1%) and good responses in 15 (34.1%), with an overall efficacy rate of 68.2%. The efficacy rate among sepsis and suspected sepsis cases was 67.6%. This treatment was also effective in 7 of 10 cases in which neutrophil counts were less than 500/mm3 through the course of administration. Laboratory abnormalities included mild eosinophilia in 1 case, slight elevation of GOT in 1 case and slight elevation of GPT in 1 case. These results suggest that CAZ is an effective and safe antibiotics for the treatment of infections in patients with hematological disorders.

AB - Fifty patiens with infections associated with hematological disorders were treated with ceftazidime (CAZ). Among them 44 cases were evaluable, including 21 with acute leukemia, 17 with malignant lymphoma, and 6 with other hematological disorders. Excellent responses were obserbed in 15 patients (34.1%) and good responses in 15 (34.1%), with an overall efficacy rate of 68.2%. The efficacy rate among sepsis and suspected sepsis cases was 67.6%. This treatment was also effective in 7 of 10 cases in which neutrophil counts were less than 500/mm3 through the course of administration. Laboratory abnormalities included mild eosinophilia in 1 case, slight elevation of GOT in 1 case and slight elevation of GPT in 1 case. These results suggest that CAZ is an effective and safe antibiotics for the treatment of infections in patients with hematological disorders.

UR - http://www.scopus.com/inward/record.url?scp=0026625755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026625755&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.45.523

DO - 10.11553/antibiotics1968b.45.523

M3 - Article

C2 - 1512938

AN - SCOPUS:0026625755

SN - 0368-2781

VL - 45

SP - 523

EP - 529

JO - The Japanese Journal of Antibiotics

JF - The Japanese Journal of Antibiotics

IS - 5

ER -

Clinical evaluation of ceftazidime monotherapy for infections complicated with hematological disorders

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this